HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clairand, I. Articles by Aubert, B. Search for Related Content PubMed PubMed Citation Articles by Clairand, I. Articles by Aubert, B.

DOSE3D: EGS4 Monte Carlo Code-Based Software for Internal Radionuclide Dosimetry

Physics Department and Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 494, Institut Gustave-Roussy, Villejuif
Commissariat à l'Énergie Atomique (CEA), Gif sur Yvette, France

Correspondence: For correspondence contact: Isabelle Clairand, PhD, Physics Department, Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France.

Correspondence: For reprints contact: Marcel Ricard, PhD, Physics Department, Institut Gustave-Roussy, 39 rue Camille Desmoulins, 94805 Villejuif Cedex, France.

ABSTRACT

MIRDOSE3 software is currently the main tool available in clinical practice to evaluate absorbed dose in nuclear medicine. Because MIRDOSE3 provides dosimetric parameters for specific anatomic models that cannot be modified by the user, it cannot be used to obtain information concerning metastases or to consider patients whose anatomy differs significantly from that of the standard models. Methods: To address some of these inconveniences, we developed an original program based on the EGS4 Monte Carlo code, DOSE3D, which calculates dosimetric parameters for anthropomorphic phantoms defined with combinatorial geometry. DOSE3D allows the user to add spheres within the phantom for simulating tumors, to change the shape of one or more organs and, for organs defined by pair, to calculate individual dosimetric parameters for each organ. The program was validated for ¹³¹I and ^99mTc by calculating S values for the Medical Internal Radiation Dose (MIRD) adult male phantom and comparing these results with data provided by MIRDOSE3. Moreover, two studies were performed to illustrate DOSE3D features. The first one concerned the evaluation of the individual influence of two bone metastases (located in the pelvis and in the lower spine and containing ¹³¹I) on testes in terms of S values compared with the influence on testes of other source organs (kidneys, liver, lungs, spleen, thyroid gland and urinary bladder contents). The second study determine the differences of S values between right and left lungs and right and left kidneys when ¹³¹I is contained in the liver. Results: The DOSE3D S values were on average within 20% of the MIRDOSE3 results for both radionuclides. Regarding the bone metastases study, S(testes–metastases) and S(testes'–any source organs) were of the same order of magnitude. In the second study, the S values ratio between right and left organs was 7.7 for the lungs and 5.2 for the kidneys. Conclusion: The agreement between DOSE3D and MIRDOSE3 results for most organs shows the validity of DOSE3D. The presented examples of calculation show that DOSE3D could provide additional data to dosimetric parameters given by MIRDOSE3 for a more patient-specific dosimetric approach.

Key Words: internal dosimetry • Monte Carlo simulation • combinatorial geometry • metastases • radiation protection

This article has been cited by other articles:

				H. Song, B. He, A. Prideaux, Y. Du, E. Frey, W. Kasecamp, P. W. Ladenson, R. L. Wahl, and G. Sgouros Lung Dosimetry for Radioiodine Treatment Planning in the Case of Diffuse Lung Metastases J. Nucl. Med., December 1, 2006; 47(12): 1985 - 1994. [Abstract] [Full Text] [PDF]

				S. Vallabhajosula, S. J. Goldsmith, K. A. Hamacher, L. Kostakoglu, S. Konishi, M. I. Milowski, D. M. Nanus, and N. H. Bander Prediction of Myelotoxicity Based on Bone Marrow Radiation-Absorbed Dose: Radioimmunotherapy Studies Using 90Y- and 177Lu-Labeled J591 Antibodies Specific for Prostate-Specific Membrane Antigen J. Nucl. Med., May 1, 2005; 46(5): 850 - 858. [Abstract] [Full Text] [PDF]

				S. Vallabhajosula, I. Kuji, K. A. Hamacher, S. Konishi, L. Kostakoglu, P. A. Kothari, M. I. Milowski, D. M. Nanus, N. H. Bander, and S. J. Goldsmith Pharmacokinetics and Biodistribution of 111In- and 177Lu-Labeled J591 Antibody Specific for Prostate-Specific Membrane Antigen: Prediction of 90Y-J591 Radiation Dosimetry Based on 111In or 177Lu? J. Nucl. Med., April 1, 2005; 46(4): 634 - 641. [Abstract] [Full Text] [PDF]

				G. Sgouros Dosimetry of Internal Emitters J. Nucl. Med., January 1, 2005; 46(1_suppl): 18S - 27S. [Abstract] [Full Text] [PDF]

				H. Yoriyaz, M. G. Stabin, and A. d. Santos Monte Carlo MCNP-4B-Based Absorbed Dose Distribution Estimates for Patient-Specific Dosimetry J. Nucl. Med., April 1, 2001; 42(4): 662 - 669. [Abstract] [Full Text]